Science Explorer Back to mapMap

Most cited papers from Paratek Pharmaceuticals (United States)

What are the most cited papers from Paratek Pharmaceuticals (United States)?

The most cited paper from Paratek Pharmaceuticals (United States) is "The history of the tetracyclines" (Mark L. Nelson, Stuart B. Levy, 2011), with 474 citations. Next come "The crystal structure of MarR, a regulator of multiple antibiotic resistance, at 2.3 A resolution." (389) and "Omadacycline for Community-Acquired Bacterial Pneumonia" (236).

Showing 50 of 61 papers. Every paper with more than 20 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 The history of the tetracyclines Mark L. Nelson, Stuart B. Levy · Annals of the New York Academy of Sciences Dec 2011 474
2 The crystal structure of MarR, a regulator of multiple antibiotic resistance, at 2.3 A resolution. Michael N. Alekshun, Stuart B. Levy, Tanya R. Mealy et al. · Nature Structural Biology Aug 2001 389
3 Omadacycline for Community-Acquired Bacterial Pneumonia Roman Stets, Monica Popescu, Joven Gonong et al. · New England Journal of Medicine Open access 6 Feb 2019 236
4 Breakthrough advances in low loss, tunable dielectric materials L. C. Sengupta, Somnath Sengupta · Materials Research Innovations Apr 1999 197
5 In Vitro and In Vivo Antibacterial Activities of Omadacycline, a Novel Aminomethylcycline Ann B. Macone, B. K. Caruso, Raina G. Leahy et al. · Antimicrobial Agents and Chemotherapy Open access 3 Dec 2013 170
6 Mechanism of Action of the Novel Aminomethylcycline Antibiotic Omadacycline Michael P. Draper, Shelagh Weir, Ann B. Macone et al. · Antimicrobial Agents and Chemotherapy Open access 17 Sep 2013 165
7 Effects of Prior Effective Therapy on the Efficacy of Daptomycin and Ceftriaxone for the Treatment of Community‐Acquired Pneumonia Peter Einar Pertel, Patricia Bernardo, Charles M. Fogarty et al. · Clinical Infectious Diseases 14 Mar 2008 163
8 Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance Kerry L. LaPlante, Abhay Dhand, Kelly Wright et al. · Annals of Medicine Open access 20 Jun 2022 162
9 Omadacycline for Acute Bacterial Skin and Skin-Structure Infections William D. O’Riordan, Sinikka Green, J. Scott Overcash et al. · New England Journal of Medicine 6 Feb 2019 157
10 Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects Mark H. Gotfried, Karolyn S. Horn, Lynne K. Garrity-Ryan et al. · Antimicrobial Agents and Chemotherapy Open access 10 Jul 2017 142
11 Silencing and Un-silencing of Tetracycline-Controlled Genes in Neurons Peixin Zhu, Marı́a Isabel Aller, Udo Baron et al. · PLoS ONE Open access 19 Jun 2007 142
12 Structure-Activity Relationship of the Aminomethylcyclines and the Discovery of Omadacycline Laura Honeyman, Mohamed Ismail, Mark L. Nelson et al. · Antimicrobial Agents and Chemotherapy Open access 9 Sep 2015 135
13 Omadacycline: Development of a Novel Aminomethylcycline Antibiotic for Treating Drug-Resistant Bacterial Infections Stephen A. Villano, Judith N. Steenbergen, Evan Loh · Future Microbiology Open access 19 Aug 2016 117
14 Brief communication: Mass spectroscopic characterization of tetracycline in the skeletal remains of an ancient population from Sudanese Nubia 350–550 CE Mark L. Nelson, Andrew R. DiNardo, Jeffery Hochberg et al. · American Journal of Physical Anthropology 17 Jun 2010 106
15 Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic Sébastien Tanaka, Judith N. Steenbergen, Stephen A. Villano · Bioorganic & Medicinal Chemistry Open access 18 Jul 2016 104
16 Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial William D. O’Riordan, Carrie Cardenas, Elliot Shin et al. · The Lancet Infectious Diseases 29 Aug 2019 98
17 Microbiology and Preclinical Review of Omadacycline James A. Karlowsky, Judith N. Steenbergen, George G. Zhanel · Clinical Infectious Diseases Open access 13 May 2019 92
18 Tetracyclines That Promote SMN2 Exon 7 Splicing as Therapeutics for Spinal Muscular Atrophy Michelle L. Hastings, Joel Berniac, Ying Hsiu Liu et al. · Science Translational Medicine Open access 4 Nov 2009 87
19 Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction Charles Michael Gibson et al. · American Heart Journal Open access 13 Oct 2020 85
20 Nonlinear response and power handling capability of ferroelectric BaxSr1−xTiO3 film capacitors and tunable microwave devices Andrey B. Kozyrev, Andrey V. Ivanov, T. B. Samoǐlova et al. · Journal of Applied Physics Nov 2000 84
21 A Randomized, Evaluator-Blind, Phase 2 Study Comparing the Safety and Efficacy of Omadacycline to Those of Linezolid for Treatment of Complicated Skin and Skin Structure Infections Gary J. Noel, Michael P. Draper, Howard I. Hait et al. · Antimicrobial Agents and Chemotherapy Open access 21 Aug 2012 82
22 Small Molecule Inhibitors of LcrF, a Yersinia pseudotuberculosis Transcription Factor, Attenuate Virulence and Limit Infection in a Murine Pneumonia Model Lynne K. Garrity-Ryan, Oak K. Kim, Joan-Miquel Balada-Llasat et al. · Infection and Immunity Open access 8 Sep 2010 73
23 Commensals upon us Michael N. Alekshun, Stuart B. Levy · Biochemical Pharmacology 8 Feb 2006 71
24 Strain-relieved Ba0.6Sr0.4TiO3 thin films for tunable microwave applications Wontae Chang, S. W. Kirchoefer, J.M. Pond et al. · Journal of Applied Physics 28 Jul 2002 66
25 An Outbreak of Pseudomonas aeruginosa Pneumonia and Bloodstream Infection Associated With Intermittent Otitis Externa in a Healthcare Worker Anne Zawacki, Edward J. OʼRourke, Gail Potter-Bynoe et al. · Infection Control and Hospital Epidemiology Dec 2004 65
26 Potency of Omadacycline against Mycobacteroides abscessus Clinical Isolates In Vitro and in a Mouse Model of Pulmonary Infection Danielle A. Nicklas, Emily C. Maggioncalda, Elizabeth Story-Roller et al. · Antimicrobial Agents and Chemotherapy Open access 18 Oct 2021 63
27 Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain Richard L Rauck, Jeffrey Potts, Qinfang Xiang et al. · Postgraduate Medicine Open access 4 Dec 2015 63
28 N-Hydroxybenzimidazole Inhibitors of the Transcription Factor LcrF in Yersinia: Novel Antivirulence Agents Oak K. Kim, Lynne K. Garrity-Ryan, Victoria J. Bartlett et al. · Journal of Medicinal Chemistry Open access 26 Aug 2009 62
29 Characterization of quality of BaxSr1−xTiO3 thin film by the commutation quality factor measured at microwaves S. V. Razumov, Andrei V. Tumarkin, M. M. Gaĭdukov et al. · Applied Physics Letters 26 Aug 2002 61
30 Novel anti-infection agents: Small-molecule inhibitors of bacterial transcription factors Todd E. Bowser, Victoria J. Bartlett, Mark C. Grier et al. · Bioorganic & Medicinal Chemistry Letters Open access 22 Aug 2007 56
31 Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis Jenni M. Vuola, Matti A. Ristola, Bernard F. Cole et al. · AIDS 21 Oct 2003 56
32 Randomized, Open-Label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects Haiying Sun, Lillian S. L. Ting, Surendra Machineni et al. · Antimicrobial Agents and Chemotherapy Open access 11 Oct 2016 55
33 Clinical disposition, metabolism andin vitrodrug–drug interaction properties of omadacycline Jimmy Flarakos, Yancy Du, Helen Gu et al. · Xenobiotica Open access 8 Aug 2016 51
34 Computational methods to estimate drug development parameters. Podlogar Bl, Ingo Muegge, Brice Lj · PubMed 2001 51
35 Versatile and Facile Synthesis of Diverse Semisynthetic Tetracycline Derivatives via Pd-Catalyzed Reactions Mark L. Nelson, Mohamed Y. Ismail, Laura McIntyre et al. · The Journal of Organic Chemistry 21 Jun 2003 50
36 New advances in antibiotic development and discovery Michael N. Alekshun · Expert Opinion on Investigational Drugs Feb 2005 50
37 Gng12 is a novel negative regulator of LPS-induced inflammation in the microglial cell line BV-2 Kelley C. Larson, Michael P. Draper, Maciej A. Lipko et al. · Inflammation Research 30 Jun 2009 49
38 An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic Steven M. Opal, Thomas M. File, Tom van der Poll et al. · Clinical Infectious Diseases Open access 13 May 2019 48
39 Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function Jolene Kay Berg, Evan L. Tzanis, Lynne K. Garrity-Ryan et al. · Antimicrobial Agents and Chemotherapy Open access 20 Nov 2017 48
40 Omadacycline for Acute Bacterial Skin and Skin Structure Infections Fredrick M. Abrahamian, George Sakoulas, Evan L. Tzanis et al. · Clinical Infectious Diseases Open access 13 May 2019 46
41 Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation Christopher G. Bunick, Jonette E. Keri, Sébastien Tanaka et al. · Antibiotics Open access 15 Apr 2021 43
42 Pharmacokinetics, Distribution, Metabolism, and Excretion of Omadacycline following a Single Intravenous or Oral Dose of 14 C-Omadacycline in Rats Wen H. Lin, Jimmy Flarakos, Yancy Du et al. · Antimicrobial Agents and Chemotherapy Open access 8 Nov 2016 43
43 Effect of Food on the Bioavailability of Omadacycline in Healthy Participants Evan L. Tzanis, Amy L. Manley, Stephen A. Villano et al. · The Journal of Clinical Pharmacology Open access 19 Aug 2016 43
44 Targeting virulence to prevent infection: to kill or not to kill? Michael N. Alekshun, Stuart B. Levy · Drug Discovery Today Therapeutic Strategies 16 Nov 2004 42
45 MarA, SoxS and Rob function as virulence factors in an Escherichia coli murine model of ascending pyelonephritis Paul Casaz, Lynne K. Garrity-Ryan, David McKenney et al. · Microbiology Dec 2006 40
46 N-Hydroxybenzimidazole inhibitors of ExsA MAR transcription factor in Pseudomonas aeruginosa: In vitro anti-virulence activity and metabolic stability Mark C. Grier, Lynne K. Garrity-Ryan, Victoria J. Bartlett et al. · Bioorganic & Medicinal Chemistry Letters Open access 13 Apr 2010 38
47 Safety and Pharmacokinetics of the Aminomethylcycline Antibiotic Omadacycline Administered to Healthy Subjects in Oral Multiple-Dose Regimens Lu Ann Bundrant, Evan L. Tzanis, Lynne K. Garrity-Ryan et al. · Antimicrobial Agents and Chemotherapy Open access 27 Nov 2017 37
48 Basis for treatment of tuberculosis among HIV-infected patients in Tanzania: the role of chest x-ray and sputum culture Muhammad Bakari, Robert D. Arbeit, Lillian Mtei et al. · BMC Infectious Diseases Open access 6 Mar 2008 37
49 Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b Study J. Scott Overcash, Pouru Bhiwandi, Lynne K. Garrity-Ryan et al. · Antimicrobial Agents and Chemotherapy Open access 12 Mar 2019 36
50 The Novel Aminomethylcycline Omadacycline Has High Specificity for the Primary Tetracycline-Binding Site on the Bacterial Ribosome Corina G. Heidrich, Sanya Mitova, Andreas Schedlbauer et al. · Antibiotics Open access 22 Sep 2016 34

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.